Approved for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who are confirmed to have osteoporosis primary in line with NICE.**All new patients**
Approved for the treatment of osteoporosis in males and juveniles in line with NHSE Commissioning Policy
Teriparatide 250microgram in 1ml prefilled pen Forsteo®
Formulary
Approved for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who are confirmed to have osteoporosis primary in line with NICE. **Exisiting patients only**
Approved for the treatment of osteoporosis in males and juveniles in line with NHSE Commissioning Policy